'Real Life' experience in a 'difficult to treat' patient population of non-Hodgkin lymphomas using the R-COMP regimen.

Doxorubicin has historically represented the first proven and most effective single-agent drug in the treatment of non-Hodgkin lymphomas (NHL).[1] As a consequence, it has been included in many com...